aspirin has been researched along with Irritable Bowel Syndrome in 5 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malakar, S | 1 |
| Raithel, M | 1 |
| Baenkler, HW | 1 |
| Naegel, A | 1 |
| Buchwald, F | 1 |
| Schultis, HW | 1 |
| Backhaus, B | 1 |
| Kimpel, S | 1 |
| Koch, H | 1 |
| Mach, K | 1 |
| Hahn, EG | 1 |
| Konturek, PC | 1 |
| Vogt, W | 1 |
| Ford, AC | 1 |
| Forman, D | 1 |
| Bailey, AG | 1 |
| Axon, AT | 1 |
| Moayyedi, P | 1 |
| Tseng, GY | 1 |
| Lin, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Self-Administered Hypnotherapy for Functional Dyspepsia[NCT03884270] | 23 participants (Actual) | Interventional | 2019-05-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Feasibility will be calculated as the proportion of participants who complete the hypnotherapy treatment program in comparison to those who drop out before treatment is completed. (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Hypnotherapy | 22 |
The BSI is an 18-item self-report questionnaire with responses on a 5-point Likert scale, ranging from 0 (not bothered by a symptom at all) to 4 (extremely bothered). Three subscales are calculated (somatization, depression, and anxiety) and the subscales can be aggregated to calculate an overall global psychological distress score. The overall score and subscale scores are converted to T-scores (with a population mean of 50 and a standard deviation of 10). Higher T-scores indicate more psychological distress and T-scores ≥63 indicate clinically significant psychological distress. The BSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.22 |
The PAGI-SYM is a 20-item self-report measure of functional dyspepsia symptom severity. The scale consists of 6 subscales (heartburn/regurgitation, nausea/vomiting, postprandial fullness/early satiety, bloating, upper abdominal pain, and lower abdominal pain). Each item is measured by a 6-point Likert scale ranging from 0 (no complaints) to 5 (severe complaints). Subscale scores are calculated by taking the mean of the items in each subscale. The total score is calculated by taking the mean of the subscale scores. Total scores range from 0 to 5, with higher scores indicating worse symptoms. The PAGI-SYM total score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3-months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -0.82 |
The NDI-SF is a 10-item self-report disease specific quality of life questionnaire. The scale consists of 5 sub-scales (tension/anxiety, interference with daily activities, disruption to regular eating/drinking, knowledge towards/control over disease, interference with work/study). Each item is measured by a 5-point Likert scale ranging from 0 (not applicable) to 4 (extremely). Individual items are aggregated to obtain a total score ranging from 0 to 100 with higher scores indicating greater impairment in quality of life. The NDI-SF score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.65 |
The VSI is a 15-item self-report questionnaire with responses ranging from 1 (strongly agree) to 6 (strongly disagree). The raw VSI score ranges from 0 (severe anxiety) to 75 (no anxiety). The VSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 10.39 |
At both baseline and end of treatment, patients will be asked to report the number of outpatient visits and procedures they have had within the last 3 months related to their functional dyspepsia symptoms (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of events (Median) | |||
|---|---|---|---|---|
| Number of outpatient visits at baseline | Number of outpatient visits at end of treatment | Number of procedures at baseline | Number of procedures at end of treatment | |
| Hypnotherapy | 2 | 1 | 2 | 1 |
At baseline and end of treatment, patients will be asked to report any medications they are taking related to their functional dyspepsia symptoms. (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of medications (Median) | |
|---|---|---|
| Medications taking at baseline | Medications taking at end of treatment | |
| Hypnotherapy | 1 | 1 |
"At the end of treatment, patients were asked an open-ended question to obtain feedback on their experience using the web-based platform for treatment. They were asked to rate their difficulty using the web platform on a 7-point scale from Extremely difficult to Extremely easy." (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely easy | Moderately easy | Somewhat easy | Neutral | Somewhat difficult | Moderately difficult | Extremely difficult | |
| Hypnotherapy | 17 | 3 | 1 | 1 | 0 | 0 | 0 |
"Treatment satisfaction will be assessed with a single item at the end of treatment asking how satisfied they were overall with their assigned treatment (on a 7-point scale from Extremely dissatisfied to Extremely satisfied)" (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely dissatisfied | Very dissatisfied | Somewhat dissatisfied | Neutral | Somewhat satisfied | Very satisfied | Extremely satisfied | |
| Hypnotherapy | 1 | 0 | 0 | 2 | 12 | 4 | 3 |
2 reviews available for aspirin and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates.
Topics: Aspirin; Basophils; Food Analysis; Food Hypersensitivity; Gastrointestinal Diseases; Humans; Immunol | 2017 |
[Gastroenterology in the elderly].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2005 |
1 trial available for aspirin and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Significance of salicylate intolerance in diseases of the lower gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Crohn Disease; Diet; Drug Hyp | 2005 |
2 other studies available for aspirin and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Dyspepsia; England; Epidemiologic | 2007 |
Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Dyspepsia | 2008 |